All Updates

All Updates

icon
Filter
Funding
Tryptamine Therapeutics secures AUD 6.5 million in initial public offering
Psychedelic Medicine
May 29, 2024
This week:
Robinhood launches joint investment accounts
Retail Trading Infrastructure
Jul 25, 2024
Partnerships
eToro partners with London Stock Exchange to expand UK stock offerings
Retail Trading Infrastructure
Jul 25, 2024
Funding
StorMagic secures funding from Palatine Growth Credit Fund
Edge Computing
Jul 25, 2024
Funding
Archera raises USD 17 million in Series B funding for product development and recruitment
Cloud Optimization Tools
Jul 25, 2024
Funding
Alto Neuroscience receives grant of USD 11.7 million to support Phase IIb clinical trials of ALTO-100
Precision Medicine
Jul 25, 2024
Partnerships
Quest Diagnostics and BD partner to develop flow cytometry-based companion diagnostics for cancer and other diseases
Precision Medicine
Jul 25, 2024
Product updates
USPACE Technology Group Limited unveils commercial optical satellites and related aerospace products
Next-gen Satellites
Jul 25, 2024
Industry news
Sweden issues study on Gripen fighter jet’s satellite launch capability
Next-gen Satellites
Jul 25, 2024
Regulation/policy
Product updates
Terran Orbital receives certification for new manufacturing facility to begin production
Next-gen Satellites
Jul 25, 2024
Partnerships
Crisalion Mobility partners with Air Chateau for pre-order of eVTOL aircraft
Passenger eVTOL Aircraft
Jul 25, 2024
Psychedelic Medicine

Psychedelic Medicine

May 29, 2024

Tryptamine Therapeutics secures AUD 6.5 million in initial public offering

Funding

  • Tryptamine Therapeutics, a clinical-stage pharmaceutical company, has secured AUD 6.5 million (USD 4.3 million) via its initial public offering.

  • Formed earlier this month through a merger between Tryp Therapeutics and Exopharm, Tryptamine Therapeutics is listed on the Australian Securities Exchange under the ticker symbol "TYP."

  • The new funds will be used toward advancing its pipeline of psilocin-based therapies into clinical trials.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.